ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00862459
Recruitment Status : Completed
First Posted : March 17, 2009
Results First Posted : January 30, 2012
Last Update Posted : January 13, 2014
Sponsor:
Information provided by (Responsible Party):
Bayer

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Triple (Participant, Investigator, Outcomes Assessor);   Primary Purpose: Diagnostic
Conditions: Brain Diseases
Spinal Cord Diseases
Interventions: Drug: Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)
Drug: Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)
Drug: Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)
Drug: OptiMARK~0.1 mmol/kg BW

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The date of the first participant's first visit was 27 August 2005. The date of the last participant's last visit was 26 March 2007.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
242 participants were screened: 5 were screening failures (withdrew consent, did not meet study criteria, other). The remaining 237 were randomized to the 0.3, 0.1, or 0.03 millimole per kilogram (mmol/kg) group.

Reporting Groups
  Description
Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875) Participant received one dose of 0.03 mmol/kg body weight (BW) of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 milliliter per second (mL/s) followed by a 20 mL 0.9% saline flush at the same rate.
Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875) Participant received one dose of 0.1 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875) Participant received one dose of 0.3 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.

Participant Flow:   Overall Study
    Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)   Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)   Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)
STARTED   72   93   72 
Participants Received Treatment   70 [1]   90 [2]   69 [3] 
COMPLETED   66   85   66 
NOT COMPLETED   6   8   6 
Lost to Follow-up                1                2                2 
Protocol Violation                1                0                0 
Withdrawal by Subject                1                1                3 
Adverse Event                0                1                0 
Personal reasons                1                0                0 
Operation                1                1                0 
Intravenous (IV) site problems                1                0                1 
Unable to hold still for imaging                0                1                0 
Inclusion/exclusion criteria not met                0                1                0 
Administrative problems                0                1                0 
[1] Number reflects all treated participants of whom 67 received Gadobutrol and 70 received OptiMARK
[2] Number reflects all treated participants of whom 90 received Gadobutrol and 88 received OptiMARK
[3] Number reflects all treated participants of whom 68 received Gadobutrol and 69 received OptiMARK



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875) Participant received one dose of 0.03 millimole per kilogram of body weight (mmol/kg BW) of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 milliliter per second (mL/s) followed by a 20 mL 0.9% saline flush at the same rate.
Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875) Participant received one dose of 0.1 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875) Participant received one dose of 0.3 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
Total Total of all reporting groups

Baseline Measures
   Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)   Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)   Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)   Total 
Overall Participants Analyzed 
[Units: Participants]
 		 70   90   69   229 
Age, Customized 
[Units: Years]
 		       
<45 years   36   42   29   107 
45-64 years   24   39   28   91 
>=65 years   10   9   12   31 
Gender 
[Units: Participants]
 		       
Female   33   58   38   129 
Male   37   32   31   100 
Race/Ethnicity, Customized 
[Units: Participants]
 		       
Caucasian   30   45   29   104 
Black   7   8   3   18 
Hispanic   3   6   3   12 
Asian   1   1   0   2 
Other   29   30   34   93 


  Outcome Measures

1.  Primary:   Categorical Visualization Score (CVS)   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 1

2.  Primary:   Difference in Number of Lesions Detected in Pre-contrast and Combined Pre-/Post-contrast MRI.   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 2

3.  Primary:   Assessment of Lesion Contrast Enhancement   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 3

4.  Primary:   Assessment of Border Delineation   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 4

5.  Primary:   Assessment of Internal Morphology   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 5

6.  Primary:   Contrast to Noise Ratio (CNR) Between White and Gray Matter With Gadobutrol Perfusion MRI   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 6

7.  Secondary:   Accuracy Comparison of Gadobutrol Doses – Detection of Matched Lesions: Blinded Reader 1   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 7

8.  Secondary:   Accuracy Comparison of Gadobutrol Doses – Detection of Matched Lesions: Blinded Reader 2   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 8

9.  Secondary:   Accuracy Comparison of Gadobutrol Doses – Detection of Matched Lesions: Blinded Reader 3   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 9

10.  Secondary:   Accuracy Comparison of Gadobutrol Doses – Detection of Matched Enhanced Lesions: Blinded Reader 1   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 10

11.  Secondary:   Accuracy Comparison of Gadobutrol Doses – Detection of Matched Enhanced Lesions: Blinded Reader 2   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 11

12.  Secondary:   Accuracy Comparison of Gadobutrol Doses – Detection of Matched Enhanced Lesions: Blinded Reader 3   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 12

13.  Secondary:   Evaluation of the Correct Diagnosis Following Gadobutrol-enhanced and Unenhanced MRI   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 13

14.  Secondary:   Evaluation of the Diagnostic Confidence Based on Unenhanced MRI and Combined Unenhanced and Enhanced MRI   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 14

15.  Secondary:   Evaluation of Perfusion Map Quality (Uncorrected Cerebral Blood Volume [CBV]) – Blinded Reader 1   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 15

16.  Secondary:   Evaluation of Perfusion Map Quality (Uncorrected Cerebral Blood Volume (CBV)) – Blinded Reader 2   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 16

17.  Secondary:   Evaluation of Perfusion Map Quality (Uncorrected Cerebral Blood Volume (CBV)) – Blinded Reader 3   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 17

18.  Secondary:   Evaluation of Perfusion Map Quality (Corrected Cerebral Blood Volume (CBV)) – Blinded Reader 1   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 18

19.  Secondary:   Evaluation of Perfusion Map Quality (Corrected Cerebral Blood Volume (CBV)) – Blinded Reader 2   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 19

20.  Secondary:   Evaluation of Perfusion Map Quality (Corrected Cerebral Blood Volume (CBV)) – Blinded Reader 3   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 20

21.  Secondary:   Evaluation of Perfusion Map Quality (Cerebral Blood Flow (CBF)) – Blinded Reader 1   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 21

22.  Secondary:   Evaluation of Perfusion Map Quality (Cerebral Blood Flow (CBF)) – Blinded Reader 2   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 22

23.  Secondary:   Evaluation of Perfusion Map Quality (Cerebral Blood Flow (CBF)) – Blinded Reader 3   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 23

24.  Secondary:   Evaluation of Perfusion Map Quality (Time to Peak (TTP)) – Blinded Reader 1   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 24

25.  Secondary:   Evaluation of Perfusion Map Quality (Time to Peak (TTP)) – Blinded Reader 2   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 25

26.  Secondary:   Evaluation of Perfusion Map Quality (Time to Peak (TTP)) – Blinded Reader 3   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 26

27.  Secondary:   Evaluation of Perfusion Map Quality (Mean Transit Time (MTT)) – Blinded Reader 1   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 27

28.  Secondary:   Evaluation of Perfusion Map Quality (Mean Transit Time (MTT)) – Blinded Reader 2   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 28

29.  Secondary:   Evaluation of Perfusion Map Quality (Mean Transit Time (MTT)) – Blinded Reader 3   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 29

30.  Secondary:   Evaluation of Perfusion Map Quality (Permeability Factor (PF) – Blinded Reader 1   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 30

31.  Secondary:   Evaluation of Perfusion Map Quality (Permeability Factor (PF) – Blinded Reader 2   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 31

32.  Secondary:   Evaluation of Perfusion Map Quality (Permeability Factor (PF)) – Blinded Reader 3   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 32

33.  Secondary:   Evaluation of Perfusion Map Parameter Value (Uncorrected Cerebral Blood Volume (CBV)) – Independent Radiologist   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 33

34.  Secondary:   Evaluation of Perfusion Map Parameter Value (Corrected Cerebral Blood Volume (CBV)) – Independent Radiologist   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 34

35.  Secondary:   Evaluation of Perfusion Map Parameter Value (Cerebral Blood Flow (CBF)) – Independent Radiologist   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 35

36.  Secondary:   Evaluation of Perfusion Map Parameter Value (Time to Peak (TTP)) – Independent Radiologist   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 36

37.  Secondary:   Evaluation of Perfusion Map Parameter Value (Mean Transit Time (MTT)) – Independent Radiologist   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 37

38.  Secondary:   Evaluation of Perfusion Map Parameter Value (Permeability Factor (PF)) – Independent Radiologist   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 38

39.  Secondary:   Evaluation of Perfusion Map Artifacts (Uncorrected Cerebral Blood Volume (CBV)) – Blinded Reader   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 39

40.  Secondary:   Evaluation of Perfusion Map Artifacts (Corrected Cerebral Blood Volume (CBV)) – Blinded Reader   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 40

41.  Secondary:   Evaluation of Perfusion Map Artifacts (Cerebral Blood Flow (CBF)) – Blinded Reader   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 41

42.  Secondary:   Evaluation of Perfusion Map Artifacts (Time to Peak (TTP)) – Blinded Reader   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 42

43.  Secondary:   Evaluation of Perfusion Map Artifacts (Mean Transit Time (MTT)) – Blinded Reader   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 43

44.  Secondary:   Evaluation of Perfusion Map Artifacts (Permeability Factor (PF)) – Blinded Reader   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 44

45.  Secondary:   Evaluation of MRI Tumor Grade Agreement With Biopsy Results by Dose Group   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 45

46.  Secondary:   Contrast to Noise Ratio (CNR) of Lesion/Gray Matter and Lesion/White Matter   [ Time Frame: up to 2 hours after the injection of study medication ]
  Show Outcome Measure 46


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
OptiMARK was used as a standard of reference in this study. A formal comparison of the efficacy of gadobutrol and OptiMARK was not specified prospectively in the statistical analysis plan. For completeness, the safety data of OptiMARK is presented.


  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Therapeutic Area Head
Organization: BAYER
e-mail: clinical-trials-contact@bayerhealthcare.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):


Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT00862459     History of Changes
Other Study ID Numbers: 91400
308200 ( Other Identifier: company internal )
First Submitted: November 26, 2008
First Posted: March 17, 2009
Results First Submitted: September 14, 2011
Results First Posted: January 30, 2012
Last Update Posted: January 13, 2014